

Special Issue

Pediatric Cancer Research from Basic Biology to Experimental Therapy

Message from the Guest Editor

New publication

MicroRNA Profiling Identifies Diagnostic and Prognostic Markers in Pediatric Sarcoma

In this article, we define the microRNA profile associated with three common pediatric sarcomas. Using multiple tissue samples from different sources including tissue microarray slides and two methods, we have detected the differential expression of miR-9-5p, miR-206, and miR-140 in Ewing's sarcoma, rhabdomyosarcoma, and osteosarcoma, respectively. The NanoString nCounter profiling method exhibited higher sensitivity in detecting microRNA profiles and differentially expressed microRNAs compared with microRNAscope which identified the in situ hybridization of specific microRNA molecules. MicroRNA expression correlated with adverse patient outcome. Our findings demonstrate that distinct miRNA profiles can differentiate pediatric sarcoma types and provide clinically relevant insights into potential diagnostic and prognostic applications.

Guest Editor

Prof. Dr. Atif Ahmed

1. Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA
2. Department of Pathology, Seattle Children's Hospitals, Seattle, WA 98105, USA

Deadline for manuscript submissions

7 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/212475

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)